Latest News Senhwa Biosciences Completes Last Patient Last Visit in the Phase I Expansion Study for Advanced Basal Cell Carcinoma with its Lead Drug Candidate Silmitasertib Aug 25 2023 Latest News Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19 Apr 28 2023 Latest News Senhwa Biosciences Announces Successful Awardee of Anticancer Pipeline, Pidnarulex, in NIH-Sponsored NExT Program Dec 01 2022 Media Coverage Senhwa Biosciences Announces Successful Awardee of Anticancer Pipeline, Pidnarulex, in NIH-Sponsored NExT Program Dec 01 2022 Media Coverage At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma Mar 28 2022 Media Coverage Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer Jan 20 2022 Publications Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 Publications Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 Publications Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic Dec 17 2020